Attruby may reduce outpatient heart failure worsening in ATTR-CM

Differences versus placebo seen within 30 days, sustained to 30 months

New analyses suggest Attruby (acoramidis) may reduce the risk of outpatient worsening heart failure, with differences seen within 30 days and sustained through 30 months in adults with transthyretin amyloid cardiomyopathy (ATTR-CM).

The analyses were based on data from the large Phase 3 ATTRibute-CM (NCT03860935) trial. In a company press release, Bridgebio, the therapy’s developer, said the findings suggest Attruby exhibits “the fastest time to impact of any disease modifying treatment in ATTR-CM.”